Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Depreciation & Amortization (CF) (2016 - 2025)

Nutex Health's Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 1.78% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $20.5 million, up 8.21%, while the annual FY2025 figure was $20.5 million, 8.21% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $5.2 million at Nutex Health, up from $5.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.3 million in Q4 2024 and bottomed at $64044.0 in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $4.3 million (2022), against an average of $3.9 million.
  • The largest YoY upside for Depreciation & Amortization (CF) was 10985.89% in 2021 against a maximum downside of 69.6% in 2021.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.8 million in 2021, then soared by 82.89% to $3.3 million in 2022, then skyrocketed by 43.13% to $4.7 million in 2023, then grew by 12.77% to $5.3 million in 2024, then dropped by 1.78% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Depreciation & Amortization (CF) are $5.2 million (Q4 2025), $5.0 million (Q3 2025), and $5.2 million (Q2 2025).